Joseph Manni Sells 1,378 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CRO Joseph Manni sold 1,378 shares of the stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $18.00, for a total transaction of $24,804.00. Following the completion of the sale, the executive owned 56,291 shares of the company’s stock, valued at approximately $1,013,238. The trade was a 2.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

CeriBell Stock Performance

Shares of NASDAQ CBLL traded up $0.03 during trading hours on Tuesday, reaching $18.80. The stock had a trading volume of 187,155 shares, compared to its average volume of 322,889. The company has a market cap of $713.27 million, a price-to-earnings ratio of -11.53 and a beta of 0.99. CeriBell, Inc. has a twelve month low of $10.85 and a twelve month high of $24.33. The business’s fifty day moving average is $19.08 and its two-hundred day moving average is $19.19. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 10.01.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. The business had revenue of $26.49 million during the quarter, compared to the consensus estimate of $26.09 million. As a group, research analysts expect that CeriBell, Inc. will post -1.69 EPS for the current year.

Analyst Ratings Changes

Several research firms recently issued reports on CBLL. BTIG Research reissued a “buy” rating and issued a $30.00 price target on shares of CeriBell in a research report on Wednesday, January 28th. Weiss Ratings cut CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 12th. Finally, Canaccord Genuity Group cut their target price on CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.20.

Hedge Funds Weigh In On CeriBell

Several hedge funds have recently added to or reduced their stakes in CBLL. Vanguard Group Inc. raised its stake in shares of CeriBell by 11.1% during the third quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after buying an additional 147,013 shares during the last quarter. KCM Capital Inc lifted its stake in CeriBell by 40.0% in the first quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock valued at $25,662,000 after buying an additional 400,000 shares during the period. Yu Fan lifted its stake in CeriBell by 10.7% in the second quarter. Yu Fan now owns 1,353,166 shares of the company’s stock valued at $25,345,000 after buying an additional 130,964 shares during the period. Bank of New York Mellon Corp grew its position in shares of CeriBell by 1,945.9% during the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after buying an additional 1,162,200 shares during the period. Finally, Novo Holdings A S grew its position in shares of CeriBell by 2.3% during the 2nd quarter. Novo Holdings A S now owns 900,000 shares of the company’s stock worth $16,857,000 after buying an additional 20,000 shares during the period.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.